呼吸器合胞体ウイルス診断の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2025年～2030年

呼吸器合胞体ウイルス診断市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の呼吸器合胞体ウイルス診断市場規模は、2025～2030年にかけてCAGR 5.81%で拡大し、2030年には87億米ドルに達すると推定されています。

RSV感染を含む呼吸器疾患に罹患する新生児人口の増加と、医療提供者による新生児診断のための支援イニシアチブは、RSV診断市場の重要な影響促進要因になると予想されます。

WHOの統計によると、米国では2014年に15万人以上の小児（5歳以下）がRSV感染症で入院し、約1万4,000人の高齢者患者が死亡しています。このことは、予測期間中、これらの疾患の検査需要を誘発すると予想されます。

さらに、2014年現在の世界の出生率は1,000人当たり18.7人であり、今後7年間で乳幼児人口が大幅に増加すると予測されています。統計によると、2014年には約1億3,420万人の出産があったと推定され、これらの出産はRSV感染症にかかりやすく、診断が必要であるため、大きな市場基盤を形成しています。

2010年、Save Babies Through Screening Foundation（SBTS）はWorld Solutions Against Infectious Disease（WSAID）とパートナーシップを結び、新生児の感染症、代謝障害、聴覚障害のスクリーニングを推進する試みを開始しました。

呼吸器合胞体ウイルス診断市場レポートハイライト

• クロマトグラフィー免疫測定法は、分子診断よりも特異性が高いため、今後7年間の2024年の市場シェアは27.38%で、同市場を独占しました。市販の検査キットには、Binax Now RSV、QuickLab RSV Test、Remel Xpect、RSV Respi-Stripなどがあります。
• 2024年には病院セグメントが41.09%のシェアで市場を独占し、予測期間中に最も速い成長率で成長すると予測されています。患者による在宅ケア診断機器への需要の高まりが、今後7年間の同セグメントの成長を牽引すると予測されています。
• 北米が市場を独占し、2024年までに41.18％以上の収益シェアを占めると予測されています。新生児スクリーニングを開始・実施するための住民の意識の高まりや、WHO、PAHO、WSAIDなどの政府機関による好意的な取り組みが成長を促進すると予想されます。
• 同市場の主要企業には、NovartisAG、Abbott、BD and Company、Ortho Clinical Diagnostics、Roche Diagnostics、Abbott Laboratories、Thermo Fisher Scientific Inc.などがあります。Roche Diagnostics、Becton Dickinson and Company、Alere Inc.などの企業によるCLIA認可やRSVアッセイの発売は、予測期間中の市場成長を押し上げると期待されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 呼吸器合胞体ウイルス診断市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 呼吸器合胞体ウイルス診断市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 呼吸器合胞体ウイルス診断市場：製品別、推定・動向分析

• 世界の呼吸器合胞体ウイルス診断市場：製品ダッシュボード
• 世界の呼吸器合胞体ウイルス診断市場：製品変動分析
• 世界の呼吸器合胞体ウイルス診断市場（製品別、収益別）
• 直接蛍光抗体法（DFA）
• 迅速抗原診断検査（RADT）
• 分子診断
• クロマトグラフィー免疫測定法
  • 重力駆動テスト
  • オリゴクロマトグラフィー（OC）
• 診断画像
• ゲルマイクロドロップレット
• フローサイトメトリー
• その他

第5章 呼吸器合胞体ウイルス診断市場：最終用途別、推定・動向分析

• 世界の呼吸器合胞体ウイルス診断市場：最終用途ダッシュボード
• 世界の呼吸器合胞体ウイルス診断市場：最終用途変動分析
• 世界の呼吸器合胞体ウイルス診断市場（最終用途、収益別）
• 病院
• ラボ
• クリニック
• その他

第6章 呼吸器合胞体ウイルス診断市場：製品、最終用途による地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • BD（Becton, Dickinson, and Company）
  • Novartis AG
  • Abbott
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • BIOMERIEUX
  • DiaSorin SpA
  • Merck KGaA
  • Coris BioConcept
  • Siemens Healthineers AG
  • Quest Diagnostics Incorporated

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 4 Global Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 5 Global Oncology Companion Diagnostic, by Region, 2018 - 2030 (USD Billion)
• Table 6 North America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
• Table 7 North America Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 8 North America Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 9 U.S. Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 10 U.S. Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 11 Canada Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 12 Canada Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 13 Mexico Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 14 Mexico Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 15 Europe Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
• Table 16 Europe Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 17 Europe Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 18 Germany Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 19 Germany Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 20 UK Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 21 UK Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 22 France Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 23 France Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 24 Italy Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 25 Italy Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 26 Spain Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 27 Spain Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 28 Denmark Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 29 Denmark Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 30 Sweden Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 31 Sweden Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 32 Norway Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 33 Norway Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 34 Asia Pacific Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
• Table 35 Asia Pacific Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 36 Asia Pacific Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 37 China Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 38 China Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 39 Japan Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 40 Japan Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 41 India Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 42 India Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 43 South Korea Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 44 South Korea Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 45 Australia Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 46 Australia Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 47 Thailand Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 48 Thailand Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 49 Latin America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
• Table 50 Latin America Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 51 Latin America Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 52 Brazil Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 53 Brazil Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 54 Argentina Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 55 Argentina Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 56 Middle East & Africa Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Billion)
• Table 57 Middle East & Africa Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 58 Middle East & Africa Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 59 South Africa Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 60 South Africa Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 61 Saudi Arabia Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 62 Saudi Arabia Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 63 UAE Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 64 UAE Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)
• Table 65 Kuwait Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Billion)
• Table 66 Kuwait Oncology Companion Diagnostic, by End use, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Respiratory Syncytial Virus Diagnostics Market Segmentation
• Fig. 8 Market Snapshot, 2024
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
• Fig. 16 Global Respiratory Syncytial Virus Diagnostics Market, for Direct Fluorescent Antibody (DFA) Method, 2018 - 2030 (USD Billion)
• Fig. 17 Global Respiratory Syncytial Virus Diagnostics Market, for Rapid Antigen Diagnostic Test (RADT), 2018 - 2030 (USD Billion)
• Fig. 18 Global Respiratory Syncytial Virus Diagnostics Market, for Molecular Diagnostics, 2018 - 2030 (USD Billion)
• Fig. 19 Global Respiratory Syncytial Virus Diagnostics Market, for Diagnostic Imaging, 2018 - 2030 (USD Billion)
• Fig. 20 Global Respiratory Syncytial Virus Diagnostics Market, for Gel Microdroplets, 2018 - 2030 (USD Billion)
• Fig. 21 Global Respiratory Syncytial Virus Diagnostics Market, for Flow Cytometry, 2018 - 2030 (USD Billion)
• Fig. 22 Global Respiratory Syncytial Virus Diagnostics Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 23 Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
• Fig. 24 Global Respiratory Syncytial Virus Diagnostics Market, for Hospitals, 2018 - 2030 (USD Billion)
• Fig. 25 Global Respiratory Syncytial Virus Diagnostics Market, for Laboratory, 2018 - 2030 (USD Billion)
• Fig. 26 Global Respiratory Syncytial Virus Diagnostics Market, for Clinics, 2018 - 2030 (USD Billion)
• Fig. 27 Global Respiratory Syncytial Virus Diagnostics Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 28 Regional Marketplace: Key Takeaways
• Fig. 29 Regional Outlook, 2024 & 2030
• Fig. 30 Global Respiratory Syncytial Virus Diagnostics Market: Region Movement Analysis
• Fig. 31 North America Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 32 U.S. Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 33 Canada Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 34 Mexico Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 35 Europe Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 36 Germany Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 37 UK Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 38 France Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 39 Italy Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 40 Spain Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 41 Denmark Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 42 Sweden Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 43 Norway Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 44 Asia Pacific Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 45 Japan Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 46 China Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 47 India Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 48 Australia Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 49 South Korea Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 50 Thailand Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 51 Latin America Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 52 Brazil Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 53 Argentina Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 54 Middle East and Africa Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 55 South Africa Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 56 Saudi Arabia Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 57 UAE Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)
• Fig. 58 Kuwait Respiratory Syncytial Virus Diagnostics Market, 2018 - 2030 (USD Billion)

Respiratory Syncytial Virus Diagnostics Market Growth & Trends:

The global respiratory syncytial virus diagnostics market size is estimated to reach USD 8.70 billion by 2030, expanding at a CAGR of 5.81% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Respiratory Syncytial Virus Diagnostics Market Report Highlights:

• Chromatographic immunoassay segment dominated the market with a share of 27.38% in 2024 over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
• Hospitals segment dominated the market with a share of 41.09% in 2024 and is anticipated to grow at fastest growth rate over the forecast period. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
• North America is anticipated to dominate the market and contribute a revenue share of over 41.18% by 2024. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
• Key players of the market include Novartis AG, Abbott, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and End use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Respiratory Syncytial Virus Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of Respiratory Syncytial Virus (RSV) Infections
    • 3.2.1.2. Advancements in diagnostics technologies
    • 3.2.1.3. Growing awareness and healthcare spending
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with advanced diagnostic tests
    • 3.2.2.2. Lack of awareness in developing reagions
• 3.3. Respiratory Syncytial Virus Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Environmental landscape

Chapter 4. Respiratory Syncytial Virus Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Global Respiratory Syncytial Virus Diagnostics Market: Product Dashboard
• 4.2. Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
• 4.3. Global Respiratory Syncytial Virus Diagnostics Market by Product , Revenue
• 4.4. Direct Fluorescent Antibody (DFA) Method
• 4.5. Rapid Antigen Diagnostic Test (RADTs)
  • 4.5.1. Rapid Antigen Diagnostic Test (RADTs) market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Molecular Diagnostics
  • 4.6.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.7. Chromatographic Immunoassay
  • 4.7.1. Chromatography immunoassay market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7.2. Gravity Driven Test
    • 4.7.2.1. Gravity driven test market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7.3. Oligochromatography (OC)
    • 4.7.3.1. Oligochromatography (OC) market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.8. Diagnostic Imaging
  • 4.8.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.9. Gel Microdroplets
  • 4.9.1. Gel microdroplets market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.10. Flow Cytometry
  • 4.10.1. Flow cytometry market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.11. Others
  • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Respiratory Syncytial Virus Diagnostics Market: End use Estimates & Trend Analysis

• 5.1. Global Respiratory Syncytial Virus Diagnostics Market: End use Dashboard
• 5.2. Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
• 5.3. Global Respiratory Syncytial Virus Diagnostics Market by End use, Revenue
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Laboratory
  • 5.5.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Clinics
  • 5.6.1. Clinics market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Respiratory Syncytial Virus Diagnostics Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. BD (Becton, Dickinson, and Company)
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Novartis AG
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Abbott
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. QuidelOrtho Corporation
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Thermo Fisher Scientific Inc.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Bio-Rad Laboratories, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. F. Hoffmann-La Roche Ltd.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. BIOMERIEUX
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. DiaSorin S.p.A.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Merck KGaA
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Coris BioConcept
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Siemens Healthineers AG
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Quest Diagnostics Incorporated
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives